Antigen News and Research

RSS

Immunologic checkpoint inhibitor shows promise in malignant mesothelioma

Tremelimumab, one of a new class of immunomodulatory monoclonal antibodies, has shown encouraging clinical activity and acceptable tolerability in patients with chemotherapy-resistant malignant mesothelioma, results of a single-arm phase II study show.

27 Sep 2013

HOOKVAC consortium awarded grant to develop, test vaccine for human hookworm

The HOOKVAC consortium, led by the Academic Medical Center at the University of Amsterdam, today announced it has been awarded a grant of six million Euros from the European Commission FP7 programme to expand the Sabin Vaccine Institute Product Development Partnership’s (Sabin PDP) work to develop and test a vaccine for human hookworm, a disease that infects 600-700 million of the world’s poorest people.

27 Sep 2013

Genomic instability in CFS is associated with less favorable outcome in patients with CaP

Detailed evaluation of a prostate cancer tumor biopsy may predict treatment outcomes for image-guided radiation therapy (IGRT) or surgery for prostate cancer, according to research presented today at the American Society for Radiation Oncology's (ASTRO's) 55th Annual Meeting.

27 Sep 2013

HOOKVAC consortium to begin first clinical testing of human hookworm vaccine in West Africa

The HOOKVAC consortium, led by the Academic Medical Center (AMC) at the University of Amsterdam, today announced it has been awarded a grant of six million Euros from the European Commission FP7 programme to expand the Sabin Vaccine Institute Product Development Partnership's (Sabin PDP) work to develop and test a vaccine for human hookworm, a disease that infects 600-700 million of the world's poorest people.

27 Sep 2013

Intestinal mucus potentially improves life of people suffering from inflammatory bowel disease

Researchers at Institut Hospital del Mar d'Investigacions M-diques (IMIM) in Barcelona, in collaboration with the Icahn School of Medicine at Mount Sinai in New York and other U.S. Institutions, have found that intestinal mucus not only acts as a physical barrier against commensal bacteria and dietary antigens, but also prevents the onset of inflammatory reactions against these agents.

27 Sep 2013

New ultra-specific test now available for prostate cancer

A new urine test for prostate cancer that measures minute fragments of RNA is now commercially available to men nationwide through the University of Michigan MLabs.

27 Sep 2013

University of Michigan offers new test to improve PSA screening for prostate cancer

More than 1 million men will undergo a prostate biopsy this year, but only about one-fifth of those biopsies will result in a cancer diagnosis.

26 Sep 2013

MIT engineers develop nanoparticles that deliver cancer vaccines to lungs

Many viruses and bacteria infect humans through mucosal surfaces, such as those in the lungs, gastrointestinal tract and reproductive tract. To help fight these pathogens, scientists are working on vaccines that can establish a front line of defense at mucosal surfaces.

26 Sep 2013

Pancreatic Cancer Imaging Agent Earns Mabvax $1.75M SBIR Award

...

24 Sep 2013

Guideline focuses on radiation therapy to be highlighted during ASTRO's 55th Annual Meeting

The American Society for Radiation Oncology will highlight the recently published Adjuvant and Salvage Radiotherapy After Prostatectomy: ASTRO/AUA Guideline during ASTRO's 55th Annual Meeting, September 22-25, 2013, in Atlanta.

24 Sep 2013

Long-term hormonal therapy has no additional benefits in men with intermediate-risk prostate cancer

A secondary analysis of the historic RTOG 9202 prostate cancer trial examined results of men with intermediate-risk prostate cancer who had received long-term hormonal therapy after radiation therapy, and concluded that there were no additional benefits when compared to short-term hormonal therapy, according to research presented today at the American Society for Radiation Oncology's (ASTRO's) 55th Annual Meeting.

24 Sep 2013

TAS therapy prior to radiation therapy yields favorable outcomes in PCa patients

A shorter course of androgen suppression therapy prior to radiation therapy, when compared to a longer course of androgen suppression therapy, yields favorable outcomes and fewer adverse effects for intermediate-risk prostate cancer patients, according to research presented today at the American Society for Radiation Oncology's (ASTRO) 55th Annual Meeting.

24 Sep 2013

Urinary pneumococcal antigen testing ‘useful in children’

Urinary antigen testing is effective in detecting invasive pneumococcal pneumonia in children, say the authors of a UK-based case–control study.

23 Sep 2013

University of Chicago researchers awarded NIH grant to develop novel multiple sclerosis treatment

Researchers from the University of Chicago have been awarded a five-year, $1.5 million grant from the National Institutes of Health to develop stimulated dendritic cell-derived exosomes that show remarkable promise as a treatment for multiple sclerosis and other neurological diseases involving loss of myelin, the insulation around nerve fibers.

18 Sep 2013

Three-gene biomarker can help determine treatment option for early prostate cancer

The level of expression of three genes associated with aging can be used to predict whether seemingly low-risk prostate cancer will remain slow-growing, according to researchers at the Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center.

13 Sep 2013

Researchers study potential role of two risk factors in preeclampsia

Although preeclampsia occurs in about 3 percent of pregnancies, it's still unforeseen in many cases. A report of new research, now in press at the Journal of Reproductive Immunology, documents how two distinct risk factors combine to affect the odds that a first-time mother could develop the sometimes life-threatening pregnancy complication.

11 Sep 2013

Discovery opens doors for developing new therapies to eradicate tumor cells, combat infections

Scientists from A*STAR's Singapore Immunology Network have discovered a new defense mechanism that the immune system utilises to combat infections. The team's discovery of how a novel protein unexpectedly activates an immune response shows how this mechanism can also be used to get rid of tumour cells.

11 Sep 2013

Roche Signs Up To $422.5M Collaboration With Inovio

...

10 Sep 2013

Hospira announces EC approval of Inflectra, Europe's first biosimilar mAb therapy

Hospira, the world's leading provider of injectable drugs and infusion technologies, today announced the European Commission (EC) approval of Inflectra™ (infliximab), Europe's first biosimilar monoclonal antibody (mAb) therapy. Inflectra has been approved for the treatment of inflammatory conditions including rheumatoid arthritis (RA), ankylosing spondylitis, Crohn's disease (CD), ulcerative colitis (UC), psoriatic arthritis (PsA) and psoriasis.

10 Sep 2013

Roche, Inovio Pharmaceuticals to develop DNA-based vaccines for prostate cancer and hepatitis B

Roche and Inovio Pharmaceuticals, Inc. announced today that they have entered into an exclusive worldwide license agreement to research, develop and commercialize Inovio's highly-optimized, multi-antigen DNA immunotherapies targeting prostate cancer and hepatitis B.

10 Sep 2013

Antigen News and Research

Immunologic checkpoint inhibitor shows promise in malignant mesothelioma

HOOKVAC consortium awarded grant to develop, test vaccine for human hookworm

Genomic instability in CFS is associated with less favorable outcome in patients with CaP

HOOKVAC consortium to begin first clinical testing of human hookworm vaccine in West Africa

Intestinal mucus potentially improves life of people suffering from inflammatory bowel disease

New ultra-specific test now available for prostate cancer

University of Michigan offers new test to improve PSA screening for prostate cancer

MIT engineers develop nanoparticles that deliver cancer vaccines to lungs

Pancreatic Cancer Imaging Agent Earns Mabvax $1.75M SBIR Award

Guideline focuses on radiation therapy to be highlighted during ASTRO's 55th Annual Meeting

Long-term hormonal therapy has no additional benefits in men with intermediate-risk prostate cancer

TAS therapy prior to radiation therapy yields favorable outcomes in PCa patients

Urinary pneumococcal antigen testing ‘useful in children’

University of Chicago researchers awarded NIH grant to develop novel multiple sclerosis treatment

Three-gene biomarker can help determine treatment option for early prostate cancer

Researchers study potential role of two risk factors in preeclampsia

Discovery opens doors for developing new therapies to eradicate tumor cells, combat infections

Roche Signs Up To $422.5M Collaboration With Inovio

Hospira announces EC approval of Inflectra, Europe's first biosimilar mAb therapy

Roche, Inovio Pharmaceuticals to develop DNA-based vaccines for prostate cancer and hepatitis B

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News